# VasGene Therapeutics

Source: https://onco.cc/companies/vasgene-therapeutics/  
OnCo record `vasgene-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

VasGene is a Los Angeles biotech developing a soluble EphB4 decoy protein that starves tumours of blood supply and reawakens immune cells, tested with checkpoint inhibitors in bladder and head and neck cancer.

## Summary

VasGene Therapeutics, based in Los Angeles and spun out of the University of Southern California, develops sEphB4-HSA, a soluble EphB4 receptor fused to albumin that blocks ephrin-B2 signalling on tumour vessels and immune cells. It has been tested with pembrolizumab in urothelial cancer and in head and neck cancer, and is registered on ClinicalTrials.gov under VasGene as lead sponsor of a phase 3 trial.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Vasgene Therapeutics, Inc; VasGene
- Tags: ctgov-sponsor
- HQ: Los Angeles, CA
- Type: biotech
- Website: https://www.vasgene.com

## Sources

- Official website: https://www.vasgene.com
- ClinicalTrials.gov: trials led by Vasgene Therapeutics, Inc: https://clinicaltrials.gov/search?lead=Vasgene%20Therapeutics%2C%20Inc
- Wikidata: https://www.wikidata.org/wiki/Q30292478

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/), [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/)
- terms: [Clinical trial](https://onco.cc/terms/clinical-trial/), [Pivotal (registrational) trial](https://onco.cc/terms/pivotal-trial/)

---
JSON: https://onco.cc/api/v1/entities/vasgene-therapeutics.json